FMA
PTCT icon

FNY Managed Accounts’s PTC Therapeutics PTCT Stock Holding History

FNY Managed Accounts’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$2K Buy
+90
New +$2.28K ﹤0.01% 415

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FNY Managed Accounts's PTCT Position: Q1 2018 in Review

FNY Managed Accounts opened a new position in PTC Therapeutics (PTCT) in Q1 2018: 90 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #415 among its holdings.

148 funds tracked by Wall St. Rank hold PTCT as of Q1 2018.

  • FNY Managed Accounts held 90 shares of PTC Therapeutics worth $2K as of Q1 2018.
  • PTC Therapeutics was a new FNY Managed Accounts position in Q1 2018.
  • PTC Therapeutics made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #415 holding.
  • 148 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.